Inventor · disambiguated record
Michael Leviten
Also filed as: LEVITEN MICHAEL · LEVITEN MICHAEL W
10 granted patents·37 pending applications·56 citations·filing 2001–2024
89Inventor score
Top patents by PatentIndex Score
47 records- 0196US10927167B2Anti-complement factor C1Q antibodies and uses thereofANNEXON INC·Filed 2020·Granted Feb 23, 2021·4 cites·19 claims
- 0292US11649279B2Anti-complement factor C1Q antibodies and uses thereofANNEXON INC·Filed 2021·Granted May 16, 2023·2 cites·21 claims
- 0392US10723788B2Anti-complement factor C1q Fab fragments and uses thereofANNEXON INC·Filed 2016·Granted Jul 28, 2020·6 cites·20 claims
- 0492US10590190B2Anti-complement factor C1q antibodies and uses thereofANNEXON INC·Filed 2019·Granted Mar 17, 2020·8 cites·22 claims
- 0592US9708394B2Anti-complement factor C1q antibodies and uses thereofANNEXON INC·Filed 2016·Granted Jul 18, 2017·10 cites·28 claims
- 0691US10316081B2Humanized anti-complement factor C1Q antibodiesANNEXON INC·Filed 2015·Granted Jun 11, 2019·10 cites·30 claims
- 0791US10227398B2Anti-complement factor C1q antibodies and uses thereofANNEXON INC·Filed 2017·Granted Mar 12, 2019·8 cites·30 claims
- 0890US11999779B2Anti-complement factor C1q Fab fragments and uses thereofANNEXON INC·Filed 2020·Granted Jun 4, 2024·2 cites·19 claims
- 0982US2025002567A1Anti-complement factor c1q fab fragments and uses thereofANNEXON INC·Filed 2024·Application pending·0 cites
- 1080US2024025974A1Humanized anti-complement factor c1q antibodies and uses thereofANNEXON INC·Filed 2023·Application pending·0 cites
- 1170US6653526B2Transgenic mice exhibiting increased susceptibility to seizuresDELTAGEN INC·Filed 2001·Granted Nov 25, 2003·2 cites·7 claims
- 1270US2021115119A1Humanized anti-complement factor c1q antibodies and uses thereofANNEXON INC·Filed 2020·Application pending·0 cites
- 1362US2019315845A1Humanized anti-complement factor c1q antibodies and uses thereofANNEXON INC·Filed 2019·Application pending·0 cites
- 1459US7164055B2HSPC150-like gene disruptions, compositions and methods related theretoDELTAGEN INC·Filed 2002·Granted Jan 16, 2007·4 cites·4 claims
- 1556US2016090425A1Anti-complement factor c1s antibodies and uses thereofANNEXON INC·Filed 2014·Application pending·0 cites
- 1655US2016159890A1Methods of treatment for alzheimer's disease and huntington's diseaseANNEXON INC·Filed 2016·Application pending·0 cites
- 1754US2006162004A1ADAM-like protease disruptions, compositions and methods related theretoLEVITEN MICHAEL W·Filed 2006·Application pending·0 cites
- 1854US2006143720A1Transgenic mice containing chordin gene disruptionsLEVITEN MICHAEL W·Filed 2006·Application pending·0 cites
- 1951US2007022487A1Huntingtin interacting protein gene disruptions, compositions and methods related theretoLEVITEN MICHAEL W·Filed 2006·Application pending·0 cites
- 2051US2006179504A1Transgenic mice containing deubiquitinated enzyme gene disruptionsLEVITEN MICHAEL W·Filed 2006·Application pending·0 cites
- 2150US2006101534A1Transgenic mice containing beta3GalT2 gene disruptionsLEVITEN MICHAEL W·Filed 2006·Application pending·0 cites
- 2249US2006101533A1Transgenic mice containing TMEM3 beta-1,3-N-acetylglucosaminyltransferase gene disruptionsLEVITEN MICHAEL W·Filed 2005·Application pending·0 cites
- 2349US2002038468A1Transgenic mice containing chordin gene disruptionsFiled 2001·Application pending·0 cites
- 2449US2010160415A1Compositions and methods for treatment of autoimmune diseaseBAYHILL THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2548US2016053023A1Methods of treatment for neuromyelitis opticaANNEXON INC·Filed 2014·Application pending·0 cites
- 2648US2002026654A1Transgenic mice containing tryptase gene disruptionsFiled 2001·Application pending·0 cites
- 2746US2003005474A1ADAM-like protease disruptions, compositions and methods related theretoFiled 2002·Application pending·0 cites
- 2845US2002133842A1Transgenic mice containing deubiquitinated enzyme gene disruptionsFiled 2001·Application pending·0 cites
- 2945US2003177514A1UBE2G2 ubiquitin-conjugating enzyme gene disruptions, compositions and methods related theretoFiled 2002·Application pending·0 cites
- 3045US2006143721A1Transgenic mice containing tryptase gene disruptionsALLEN KEITH D·Filed 2006·Application pending·0 cites
- 3145US2002133841A1Transgenic mice containing huntingtin interacting protein gene disruptionsFiled 2001·Application pending·0 cites
- 3244US2003014771A1Transgenic mice containing USP3-like deubiquitinating enzyme gene disruptionsFiled 2002·Application pending·0 cites
- 3344US2002162131A1Transgenic mice containing cerberus gene disruptionsFiled 2001·Application pending·0 cites
- 3443US2003009779A1Transgenic mice containing ubiquitin enzyme gene disruptionsFiled 2002·Application pending·0 cites
- 3543US2003005477A1Transgenic mice containing beta3GalT2 gene disruptionsFiled 2002·Application pending·0 cites
- 3643US2016326237A1Methods of treatment for guillain-barre syndromeANNEXON INC·Filed 2015·Application pending·0 cites
- 3743US2003046720A1USP3-like deubiquitinating enzyme gene disruptions, compositions and methods related theretoFiled 2002·Application pending·0 cites
- 3843US2002194627A1Transgenic mice containing ubiquitin protein ligase E3 gene disruptionsFiled 2001·Application pending·0 cites
- 3942US2002022719A1Transgenic mice containing ubiquitin-specific protease gene disruptionsFiled 2001·Application pending·0 cites
- 4041US2002174450A1Transgenic mice containing cash gene disruptionsFiled 2001·Application pending·0 cites
- 4141US2002023275A1Transgenic mice containing matrix metalloprotease gene disruptionsFiled 2001·Application pending·0 cites
- 4240US2002026653A1Transgenic mice containing serine protease gene disruptionsFiled 2001·Application pending·0 cites
- 4340US2010048679A1Polynucleotide therapyBAYHILL THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 4440US2010130593A1Methods and immune modulator nucleic acid compositions for preventing and treating diseaseBAYHILL THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 4537US2017081700A1Methods for screening for inhibitors of complement serine proteasesANNEXON INC·Filed 2015·Application pending·0 cites
- 4636US2018092991A1Compositions and methods for treatment of insulin-dependent diabetes mellitusGARREN HIDEKI·Filed 2010·Application pending·0 cites
- 4733US2002170075A1Transgenic mice comprising beta-1,3-N-acetyllactosamine disruptionsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Leviten files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →